Organisation paid for research Program year 2025 Source: CMS Open Payments

Colorado Kidney Care

Neither a doctor nor a teaching hospital

Research payments

$2,944,991

35 payments

Through program year 2025, Colorado Kidney Care is reported as receiving $2,944,991 in research payments, across 35 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $2,231,178 19
2024 Research $524,370 5
2022 Research $58,249 2
2020 Research $117,963 5
2019 Research $13,231 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,625,849 6 payments
  2. Alnylam Pharmaceuticals Inc. $120,906 21 payments
  3. Akebia Therapeutics Inc $113,417 3 payments
  4. Otsuka Pharmaceutical Co., Ltd. $58,249 2 payments
  5. Biogen, Inc. $20,997 1 payment
  6. Retrophin, Inc. $5,573 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases $1,752,592 3 payments
  2. A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy $869,902 2 payments
  3. A Phase 1B, Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease $113,417 3 payments
  4. Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) $108,702 17 payments
  5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of Vis649 in Participants With Immunoglobulin A (Iga) Nephropathy $58,249 2 payments
  6. An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) (EAGLE) $20,997 1 payment
  7. A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis ALECT2 Disease $7,658 2 payments
  8. Duet $4,629 1 payment
  9. A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease $4,546 2 payments
  10. An Open-label, Multicenter Study to Assess the Effect of Zigakibart Treatment on Histologic, Circulating, and Excreted Markers of Kidney Disease and Dysfunction in Adult Patients With IgA Nephropathy. $3,355 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record